Core Viewpoint - BioLife Solutions, Inc. (BLFS) is experiencing significant selling pressure, with a 17.6% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst consensus for better-than-expected earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 indicating oversold conditions [2]. - BLFS has an RSI reading of 29.79, suggesting that the heavy selling pressure may be exhausting, indicating a potential trend reversal [5]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for BLFS, with a 6.9% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - BLFS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating strong potential for a turnaround [8].

Group 1 - BioLife (BLFS) is implementing a back-to-basics approach, focusing on its core competence in biopreservation media, specifically CryoStor and HypoThermosol, which is contributing to a turnaround in FY25 [2] - The company is concentrating on vials, which is one of the two remaining businesses, indicating a strategic shift towards its strengths [2] - The service SHU Growth Portfolio offers a portfolio and watchlist of small, high-growth potential stocks, emphasizing a buy and hold strategy with tranche purchases [1][2]

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 11% over the past four weeks, closing at $24.2, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $32.67, representing a 35% upside [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1, where the lowest estimate is $31.00 (28.1% increase) and the highest is $34.00 (40.5% increase) [2] - A smaller standard deviation indicates greater agreement among analysts regarding price targets, which is crucial for understanding the variability of estimates [2][9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher for BLFS, which is a positive indicator for potential stock upside [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.9% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be wise due to historical inaccuracies in predicting stock price movements [3][10]

Financial Data and Key Metrics Changes - Total revenue for 2025 grew 29% to $96 million, landing at the high end of guidance, which was raised twice in the second half of the year [6][14] - Adjusted EBITDA increased to $25 million or 26% of revenue, up from $13 million or 18% in 2024 [6][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 of the prior year [17] Business Line Data and Key Metrics Changes - In Q4, total revenue reached $24.8 million, increasing 20% year-over-year, primarily driven by the biopreservation media (BPM) franchise [7][14] - BPM product line accounted for approximately 85% of total revenue, with commercial BPM customers accounting for nearly 50% of revenue, up from the low 40s range in 2024 [7][8] - Full year growth across all product lines except hPL media, which was flat year-over-year due to import restrictions in China [15] Market Data and Key Metrics Changes - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [8] - Anticipation of up to 5 unique therapy approvals over the next 12 months, along with 1 new indication and at least 1 geographic expansion [9] Company Strategy and Development Direction - The company aims to drive sustainable, profitable growth and shareholder value with a streamlined portfolio centered on market-leading consumables [5] - Focus on expanding role within clinical and commercial programs beyond biopreservation media, with cross-sell opportunities expected to increase revenue per patient dose by 2 to 3 times [9][10] - Strategic distribution and product development agreement with Qkine Limited to expand product offerings in cytokines [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, supported by encouraging clinical data and strategic investments by large pharma [12] - Guidance for 2026 includes revenue between $112 million and $115 million, reflecting growth of 17%-20% [11][20] - Expectation of full year positive GAAP net income for the first time in many years, along with further expansion of adjusted EBITDA margins [21] Other Important Information - Cash and marketable securities balance at December 31, 2025, was $120.2 million, up from $105.4 million at December 31, 2024 [19] - The company implemented ERP manufacturing modules to enhance operational efficiency [14] Q&A Session Summary Question: Guidance assumptions between commercial and clinical - Management expects commercial customers to represent 50%-55% of total revenue in 2026, with no significant uptick in clinical customer orders observed [25] Question: Bag yield impact on margins - Management indicated a 2 to 3-point headwind on gross margin in the second half of 2025 due to bag yield issues, with improvements expected by Q4 2026 [27] Question: Exposure to CAR T market - Over 80% of commercial exposure is related to CAR T therapies, with patient access being a key constraint to growth [33] Question: Cross-selling initiative success - Growth from non-BPM tools is expected to outpace BPM growth, with metrics on customer usage of multiple products being a future goal [40] Question: Partnership with Qkine - The partnership is seen as a long-term strategic move, with revenue expected to materialize in 2026 [46] Question: Potential acquisitions in biopreservation - Management is monitoring potential acquisitions but has not identified any that provide a competitive advantage beyond what is already offered [61]

Financial Performance - In 2025, total revenue grew 29% to $96 million, reaching the high end of guidance, with Q4 revenue at $24.8 million, a 20% year-over-year increase [6][15][16] - Adjusted EBITDA for Q4 was $6.9 million, or 28% of revenue, compared to $3.7 million or 18% in Q4 2024; full year adjusted EBITDA was $25 million or 26% of revenue, up from $13.3 million or 18% in the prior year [19][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 2024; full year adjusted net income was $6.3 million, compared to an adjusted net loss of $2.9 million in the prior year [18][19] Business Line Performance - The biopreservation media (BPM) product line accounted for approximately 85% of total revenue, with commercial BPM customers contributing nearly 50% of revenue, up from the low 40s range in 2024 [8][6] - Growth was observed across all product lines except for hPL media, which remained flat due to import restrictions in China [16] Market Dynamics - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [9] - The company anticipates up to five unique therapy approvals and one geographic expansion in the next 12 months, indicating a positive regulatory environment [10] Strategic Direction - The company aims to expand its role in clinical and commercial programs beyond biopreservation media, with a focus on cross-selling additional cell processing tools [10][11] - A strategic distribution agreement with Qkine Limited was established to enhance the product offering in cytokines, complementing the emerging hPL product line [12] Management Commentary - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, citing favorable macro conditions and increased strategic investments by large pharma [13] - The company expects to achieve full year positive GAAP net income for the first time in many years and further expansion of adjusted EBITDA margins in 2026 [22] Other Important Information - The company implemented ERP manufacturing modules to enhance operational efficiency without disrupting operations [15] - Cash and marketable securities balance at year-end 2025 was $120.2 million, up from $105.4 million at year-end 2024 [20] Q&A Session Summary Question: Can you provide more color on the assumptions between commercial and clinical growth? - Management expects commercial customers to represent 50%-55% of total revenue in 2026, with no significant uptick in clinical customer orders observed yet [25][26] Question: What was the impact of bag yield on margins in the second half of 2025? - Management indicated a 2-3 point headwind on gross margin due to bag yield issues, with solutions expected to be implemented by Q4 2026 [27][28] Question: What is the company's exposure to the CAR-T market? - Over 80% of commercial exposure is related to CAR-T therapies, with patient access being a key constraint to growth [34] Question: Can you elaborate on the cross-selling initiative? - The growth rate of non-BPM tools is expected to outpace BPM tools, with a focus on tracking customer usage of multiple products [41][42] Question: What is the margin profile for the new partnership with Qkine? - Specific margins were not disclosed, but the partnership is viewed as a long-term strategic move rather than a short-term revenue generator [46][48] Question: Are there plans for further acquisitions in biopreservation? - Management is monitoring potential acquisitions but has not identified any that would provide a competitive advantage beyond the recent PanTHERA acquisition [62]

Financial Data and Key Metrics Changes - Total revenue for 2025 grew 29% to $96 million, landing at the high end of guidance, which was raised twice in the second half of the year [5][13] - Adjusted EBITDA increased to $25 million or 26% of revenue, up from $13 million or 18% in 2024 [5][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 of the prior year [17] Business Line Data and Key Metrics Changes - In Q4, total revenue reached $24.8 million, increasing 20% year-over-year, primarily driven by the biopreservation media (BPM) franchise [6][13] - BPM product line accounted for approximately 85% of total revenue, with commercial BPM customers accounting for nearly 50% of revenue, up from the low 40s range in 2024 [6][14] - The hPL media business was flat year-over-year due to import restrictions in China, which have since been lifted [14] Market Data and Key Metrics Changes - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [7] - Anticipation of up to 5 unique therapy approvals over the next 12 months, along with 1 new indication and at least 1 geographic expansion [9] Company Strategy and Development Direction - The company aims to drive sustainable, profitable growth and shareholder value with a streamlined portfolio centered on market-leading consumables [4] - A strategic distribution and product development agreement with Qkine Limited was established to expand the product offering into cytokines, complementing the emerging hPL product line [10][11] - The company is focused on increasing adoption of non-BPM products and driving operational excellence across the organization [71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, supported by favorable regulatory developments and increased strategic investments by large pharma [12] - For 2026, the company issued guidance of total revenue between $112 million and $115 million, reflecting growth of 17%-20% [11][20] - Expected full year positive GAAP net income for the first time in many years, along with further expansion of adjusted EBITDA margins compared to 2025 [21] Other Important Information - The company implemented ERP manufacturing modules in February 2026, enhancing automated processes and controls for manufacturing and accounting functions [13] - Cash and marketable securities balance at December 31, 2025, was $120.2 million, an increase from $105.4 million at December 31, 2024 [19] Q&A Session Summary Question: Guidance assumptions between commercial and clinical - Management expects commercial customers to represent 50%-55% of revenue in 2026, with no significant uptick seen in clinical activity levels yet [25][26] Question: Bag yield impact on margins - The bag yield issue was about a 2 to 3-point headwind on gross margin in the second half of 2025, with solutions expected to be implemented by Q4 2026 [26][27] Question: Exposure to CAR T market - Over 80% of commercial exposure is related to CAR T therapies, with patient access being a key constraint to overall adoption [32] Question: Cross-selling initiative success - The growth rate of non-BPM tools is expected to outpace BPM, with metrics on customer usage of multiple products being a future goal [40][41] Question: Qkine partnership details - The partnership with Qkine is seen as a long-term strategic move, with revenue expected to materialize in the future [46][47]

Revenue Sources - Approximately 29%, 32%, and 29% of the company's revenue in the years ended December 31, 2025, 2024, and 2023, respectively, came from three major customers [78]. - The company derived approximately 82%, 80%, and 82% of its revenue from CryoStor products in the same years [78]. - Approximately 20% of the company's revenue for the year ended December 31, 2025, was derived from customers located outside the United States, primarily in Europe, the Middle East, and Africa [164]. Competition and Market Risks - The company faces significant competition in the life sciences industry, with potential risks of product obsolescence due to technological advancements by competitors [76]. - The company may face increased competition and reduced product revenue opportunities upon patent expirations, with no guarantee of patent term extensions [116]. - Healthcare reform measures may adversely affect the ability to sell products profitably, potentially limiting commercial opportunities and impacting stock prices [98]. Supply Chain and Manufacturing Risks - Manufacturing difficulties could lead to delayed shipments or supply constraints, adversely affecting product revenue and results of operations [89]. - The company is dependent on suppliers and third-party manufacturers, with potential disruptions in the supply chain impacting manufacturing capabilities [91]. - The global supply chain is subject to disruptions due to geopolitical and trade issues, which may affect operations [93]. - The company faces risks related to temporary closures of manufacturing facilities, supply shortages, and increased costs for employee health protection measures [168]. Regulatory and Compliance Risks - The company complies with cGMP requirements but may face future regulatory challenges that could delay product sales or increase expenses [94]. - Compliance with international regulations may incur significant expenses and could lead to product recalls or penalties if not maintained [95]. - Compliance with evolving laws and regulations regarding AI may impose significant operational and financial burdens on the company [136]. Financial Condition and Performance - The net carrying value of goodwill and other intangible assets as of December 31, 2025, totaled $212.8 million [81]. - The company's operating results are expected to fluctuate significantly due to various factors, including customer demand and competitive pressures [80]. - Material weaknesses in internal control over financial reporting were identified, which could affect the accuracy and timeliness of financial results [150]. - The company has accumulated significant net operating losses (NOLs) but may face limitations in utilizing them due to insufficient profits in certain jurisdictions [157]. - Changes in tax laws and regulations could adversely affect the company's financial condition and results of operations [156]. Legal and Litigation Risks - The company faces risks from various claims and litigation that could harm its reputation and financial condition [100]. - Securities litigation and stockholder activism could lead to increased expenses and impact capital deployment opportunities [101]. - The company may incur substantial costs due to litigation related to patent and intellectual property rights, which could materially harm its financial condition [119]. - The company may face claims regarding the wrongful use of confidential information by employees or contractors, which could result in costly litigation [126]. Intellectual Property Risks - The company relies on patent rights and other intellectual property to maintain its competitive position, but these protections may not be sufficient [112]. - The validity and enforceability of patents are uncertain, which could impact the company's ability to protect its technologies [113]. - Trade secrets are difficult to maintain, and unauthorized disclosure could harm the company's competitive position [114]. - The company may not be able to protect its intellectual property rights globally, leading to potential competition from unprotected technologies [117]. Stockholder and Governance Issues - A significant stockholder, Casdin Capital, LLC, owns 5,957,165 shares, representing 12.4% of the outstanding shares, influencing corporate actions [140]. - The Board has the authority to issue preferred stock without further stockholder action, which could affect corporate governance [145]. - The company has not paid dividends in the past and does not expect to do so in the foreseeable future, retaining funds for business operations and expansion [141]. Economic and Environmental Risks - Tariffs and trade policies may impact the availability of supplies, customer demand, and overall business operations [160]. - Political tensions and trade restrictions could reduce global trade and adversely affect the company's financial condition [161]. - Unfavorable currency exchange rate fluctuations may impact operating margins and sales revenue [163]. - Climate change presents risks that could negatively affect the company's business and financial condition, including potential costly changes to facilities and increased energy costs [167]. - Public health crises, such as the COVID-19 pandemic, have created significant volatility and uncertainty, adversely affecting business operations and financial condition [165]. - Future public health crises may lead to material adverse effects on manufacturing, supply chain, and profitability, depending on various uncontrollable factors [166]. Technology and Cybersecurity Risks - The company is integrating AI and machine learning technologies into its operations, but faces risks related to the development and deployment of these technologies [134]. - Cybersecurity risks and data breaches could materially adversely impact the company's business and financial condition [129]. - The company cannot guarantee that its security measures will effectively prevent unauthorized access to its systems and information [130]. Interest Rate and Investment Risks - Interest rate risk is primarily related to investments in available-for-sale securities and long-term debt, with fluctuations in interest rates not materially impacting financial statements [271].

Financial Performance - BioLife Solutions, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year ended December 31, 2025[4]. - The report does not provide specific revenue figures or growth percentages in the available content[4]. Compliance and Reporting - The report was filed on January 12, 2026, indicating the company's compliance with the Securities Exchange Act of 1934[4]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. - The financial results will not be deemed "filed" under the Exchange Act, limiting liability under Section 18[5]. - The Chief Financial Officer, Troy Wichterman, signed the report, indicating executive oversight[10]. Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BLFS[2]. - The company operates from its headquarters located at 3303 Monte Villa Parkway, Bothell, WA[2]. Additional Information - The press release detailing the financial results is attached as Exhibit 99.1[6]. - No information on new products, technologies, market expansion, or mergers and acquisitions was provided in the current report[4].

Core Viewpoint - BioLife Solutions, Inc. is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, along with a business update [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company provides solutions that maintain the health and function of biologic materials during various stages including collection, development, storage, and distribution [1] Financial Reporting - The financial results will be discussed in a conference call and live webcast scheduled for 4:30 PM ET (1:30 PM PT) on the release date [1] - Access to the webcast will be available through the Investor Relations page of the BioLife Solutions website [1] Contact Information - The Chief Financial Officer, Troy Wichterman, can be contacted for media and investor relations inquiries [1]

Core Insights - BioLife Solutions has signed a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products for cell and gene therapy manufacturing, enhancing its product portfolio in the rapidly growing cytokines market [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, focusing on maintaining the health and function of biologic materials during various stages of therapy development [1] - Qkine Limited specializes in high-purity, bioactive growth factors and cytokines, supporting stem cell and regenerative medicine research [1] Market Potential - The global cytokines market is currently estimated at $500 million annually and is projected to grow at a mid-teens compound annual growth rate, potentially reaching $1 billion by 2030, driven by the expansion of CGT development pipelines [1] Strategic Collaboration - The agreement grants BioLife exclusive worldwide distribution rights to specific Qkine products for the CGT market and non-exclusive rights to other Qkine products, indicating a strategic partnership aimed at enhancing product offerings [1] - Both companies plan to collaborate on a process development and validation program to utilize BioLife's proprietary CellSeal® Connect vial system, which is designed for closed system and automated CGT workflows [1] Leadership Comments - Roderick de Greef, BioLife's Chairman and CEO, emphasized the strategic nature of the partnership, highlighting the complementary nature of Qkine's products to BioLife's existing offerings [1] - Dr. Robert Scoffin, Qkine's CEO, expressed excitement about the collaboration, noting the combined expertise in cytokine innovation and BioLife's established customer relationships in the CGT market [1]